Navigation Links
Pregnancy hormone key to repairing nerve cell damage

The mystery of why multiple sclerosis (MS) tends to go into remission while women are pregnant may be the secret to overcoming the devastating neurodegenerative disease, according to University of Calgary researchers who have shown that a pregnancy-related hormone is responsible for rebuilding the protective coating around nerve cells.

In a paper to be published in the February 21 issue of The Journal of Neuroscience, a team of researchers from the U of C's Faculty of Medicine reports that a study conducted on mice found that the hormone prolactin encourages the spontaneous production of myelin, the fatty substance that coats nerve cells and plays a critical role in transmitting messages in the central nervous system. A collaboration between the laboratories of Drs. Samuel Weiss and V. Wee Yong of the Hotchkiss Brain Institute, the study is the first to determine that prolactin, which increases in the body during pregnancy, is directly responsible for the formation of new myelin in the brains and spinal cords of pregnant mice. Further, when non-pregnant mice with MS-like lesions were injected with prolactin, their myelin was also repaired.

The research was based on evidence that MS, which is more common in women than men, goes into remission when women become pregnant. MS is a neurodegenerative disease where the body's own immune system attacks the myelin surrounding nerves, leading to progressive loss of sensation and movement. MS affects approximately 2.5 million people worldwide and Canadians have one of the highest rates of the disease in the world.

"It is thought that during pregnancy, women's immune systems no longer destroyed the myelin," said Weiss, director of the Hotchkiss Brain Institute and senior author of the study. "However, no previous study has tested whether pregnancy actually results in the production of new myelin, which may lead to improvement of symptoms." The paper's findings represent the first example of a natural, biological mechanism that produces new myelin in the adult brain and spinal cord and identifies prolactin as a potential therapeutic substance for future testing in people with MS.

"Agents promoting remyelination will be beneficial not only for typical demyelinating diseases like MS," says Dr. Fred (Rusty) Gage, of the Salk Institute, "but also for many other neurological disorders, such as spinal cord injuries and stroke." Gage, an international leader in nervous system repair, was not involved in this study.

Subsequent tests of prolactin in animal models of MS will be required before testing of prolactin on humans can take place, but MS researchers are hopeful human trials can take place within the next several years.

"This discovery has the potential to take MS therapy a step further than current treatments that stabilize the disease in its early stages. By promoting repair, which is the goal of prolactin therapy, we have hope of actually improving symptoms in people with MS," says Dr. Luanne Metz, director of the Calgary MS Clinic in the Department of Clinical Neurosciences, University of Calgary and Calgary Health Region.

The study, authored by Weiss, Christopher Gregg, Viktor Shikar, Peter Larsen, Gloria Mak, Andrew Chojnacki and Yong, compared pregnant and virgin female mice of the same age and found that pregnant mice had twice as many myelin-producing cells, called oligodendrocytes, and continued to generate new ones during pregnancy. By chemically destroying myelin around nerve cells, the researchers found that pregnant mice had twice as much new myelin two weeks following the damage as virgin mice and that introducing prolactin mimicked the effects of pregnancy on myelin production and repair in mice that weren't pregnant.

"The results of this study should be well received by people living with MS today," said Dr. William McIlroy, national medical advisor for the Multiple Sclerosis Society of Canada. "It represents a new insight of how we might be able to reverse some of the effects of the disease and improve the quality of life for those who live under its influence."


'"/>

Source:University of Calgary


Related biology news :

1. Pregnancy drugs can affect grandkids
2. Female sex hormones play a vital role in defense against sexually transmitted diseases
3. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
4. Measuring hormone cuts antibiotic use in half in pneumonia patients
5. Alcohol consumption disrupts breastfeeding hormones
6. VCU study shows hormone-like molecule kills cells that cause inflammation in allergic disease
7. University of Nevada, Reno research team discovers hormone that causes malaria mosquito to urinate
8. Penguin chicks exposed to human visitors experience spike in stress hormone
9. Suppressing growth hormone in early adulthood may prevent cancer
10. Growth hormone is made in the brain, report scientists
11. Learning and memory stimulated by gut hormone
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/16/2016)... Research and Markets has announced the addition of the ... report to their offering. ... The biometric vehicle access system market, in terms ... from 2016 to 2021. The market is estimated to be USD ... by 2021. The growth of the biometric vehicle access system market ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... 18, 2017   Boston Biomedical , an industry ... target cancer stemness pathways, will feature data from two ... the 2017 ASCO Gastrointestinal Cancers Symposium, held from January ... Napabucasin is an orally-administered investigational agent designed ... Cancer stem cells (CSCs) possess the property of ...
(Date:1/18/2017)... ... 18, 2017 , ... Whitehouse Labs has furthered its efforts ... Inc. (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has ... in 2017. Extractable & Leachable evaluations have become increasingly more vital to successful ...
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, LLC, ... research and genetic testing lab equipment from two different leading institutes. This highly specialized ... regions of the United States. This 1-day online auction will take place on ...
(Date:1/18/2017)... , Jan. 18, 2017  Caris Life Sciences, ... Lustgarten Foundation, the largest private funder of pancreatic ... trial evaluating the impact of immunotherapy in the ... trial enrollment services to identify potential trial candidates ... between treating physicians and study investigators. The Lustgarten ...
Breaking Biology Technology: